Emergent BioSolutions

Latest news

• NaxSwab OTC novel naloxone nasal swab successfully administered by children and adults to potentially rescue someone from an opioid overdose in study
  13 April 2023
• U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ Narcan Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
  29 March 2023
• New Drug Application for RiVive Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA
  26 December 2022
• Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter Narcan (naloxone HCl) Nasal Spray
  6 December 2022
• Narcan (naloxone HCl) Nasal Spray 2mg Approved by U.S. Food and Drug Administration
  25 January 2017
• FDA Approves Vaxchora (Cholera Vaccine, Live, Oral) to Prevent Cholera in Travelers
  11 June 2016
• FDA Approves BioThrax for Use After Known or Suspected Anthrax Exposure
  23 November 2015
• FDA Approves Narcan (naloxone) Nasal Spray to Treat Opioid Overdose
  18 November 2015
• Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA to FDA for Narcan (naloxone) Nasal Spray
  29 July 2015
• FDA Approves Anthrasil, [Anthrax Immune Globulin Intravenous (Human)], for Inhalation Anthrax
  25 March 2015

Drugs Associated with Emergent BioSolutions Inc.

Emergent BioSolutions Inc. manufactures, markets and/or distributes more than 6 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.